Limbitrol Ds

Depression, Enterocolitis, Anxiety Disorders + 6 more

Treatment

8 FDA approvals

20 Active Studies for Limbitrol Ds

What is Limbitrol Ds

Chlordiazepoxide

The Generic name of this drug

Treatment Summary

Chlordiazepoxide is a medication used to treat anxiety, seizures, and memory loss. It can also be used to help with alcohol withdrawal symptoms.

Librax

is the brand name

image of different drug pills on a surface

Limbitrol Ds Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Librax

Chlordiazepoxide

1966

112

Approved as Treatment by the FDA

Chlordiazepoxide, otherwise known as Librax, is approved by the FDA for 8 uses like Enterocolitis and Irritable Bowel Syndrome .

Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Irritable Bowel Syndrome

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

Irritable Bowel Syndrome (IBS)

Used to treat Irritable Bowel Syndrome (IBS) in combination with Clidinium

acute Enterocolitis

Used to treat acute Enterocolitis in combination with Clidinium

Depression

Used to treat Depression in combination with Amitriptyline

Peptic Ulcer Disease

Used to treat Peptic Ulcer Disease in combination with Clidinium

Anxiety

Used to treat moderate to severe anxiety in combination with Amitriptyline

moderate to severe symptoms

Used to treat moderate to severe symptoms in combination with Amitriptyline

Effectiveness

How Limbitrol Ds Affects Patients

Chlordiazepoxide has calming, sleep-inducing, appetite-stimulating, and mild pain-relieving effects. It seems to stop some types of activity in the brain stem. Research has shown that it could affect the limbic system in the brain, which is involved in emotion. In one study, hostile monkeys became calmer after taking chlordiazepoxide. Other studies have found that the drug could reduce fear and aggression in rats that had been made aggressive due to brain damage. The dose of chlordiazepoxide used to reduce aggression was much lower than the dose needed to cause drowsiness.

How Limbitrol Ds works in the body

Chlordiazepoxide works by binding to certain sites in the brain, which allows it to increase the effectiveness of a neurotransmitter called GABA. This induces relaxation and reduces anxiety, as well as providing sedative and muscle-relaxing effects.

When to interrupt dosage

The suggested dosage of Limbitrol Ds is subject to the diagnosed disorder, including Syndrome, moderate to severe symptoms and Depression. The quantity of dosage is contingent upon the method of administration outlined in the table below.

Condition

Dosage

Administration

moderate to severe symptoms

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Depression

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Enterocolitis

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety Disorders

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Irritable Bowel Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Peptic Ulcer Disease

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Syndrome

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Anxiety

, 5.0 mg, 10.0 mg, 25.0 mg

, Oral, Capsule, Capsule - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, Tablet - Oral, Tablet, film coated - Oral, Tablet, film coated

Warnings

There are 20 known major drug interactions with Limbitrol Ds.

Common Limbitrol Ds Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Deutetrabenazine

Major

The risk or severity of sedation and somnolence can be increased when Chlordiazepoxide is combined with Deutetrabenazine.

Ethanol

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Methadone

Major

Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Chlordiazepoxide is combined with Oliceridine.

Limbitrol Ds Toxicity & Overdose Risk

The lethal dose of this drug in rats is 537mg/kg if taken orally. Overdosing on this drug may cause shallow breathing, muscle weakness, and excessive sleepiness.

image of a doctor in a lab doing drug, clinical research

Limbitrol Ds Novel Uses: Which Conditions Have a Clinical Trial Featuring Limbitrol Ds?

Currently, 794 active clinical trials are examining the potential of Limbitrol Ds in reducing moderate to severe Anxiety Disorders and related Syndromes.

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

44 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3

Enterocolitis

0 Actively Recruiting

Irritable Bowel Syndrome

3 Actively Recruiting

Not Applicable, Early Phase 1

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Peptic Ulcer Disease

0 Actively Recruiting

Anxiety

1 Actively Recruiting

Not Applicable

Anxiety

0 Actively Recruiting

Depression

269 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

moderate to severe symptoms

0 Actively Recruiting

Limbitrol Ds Reviews: What are patients saying about Limbitrol Ds?

5

Patient Review

1/12/2008

Limbitrol Ds for Anxiousness associated with Depression

4

Patient Review

1/16/2010

Limbitrol Ds for Anxiousness associated with Depression

This prescription has allowed me to finally get a good night's sleep. I have Rheumatoid Arthritis, so previously it was difficult for me to even fall asleep due to discomfort. Ambien helped me fall asleep but I would always wake up after a few hours. This medication keeps me asleep for around 7 hours, which is great!

3

Patient Review

3/15/2010

Limbitrol Ds for Osteoporosis

This treatment really helped me. I'm grateful for modern medicine.

2.3

Patient Review

3/20/2013

Limbitrol Ds for Anxiousness associated with Depression

I felt okay the first week, but then began to experience increased levels of depression and anxiety. These nightmares and thoughts were really terrible, so I stopped taking the medication. I changed my diet and started working out, which made me feel a lot better. A year later and I'm doing things I never thought possible- like rock climbing with friends.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about limbitrol ds

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do they still make Limbitrol?

"The Limbitrol brand name has been discontinued in the U.S. Generic versions of the product have been approved by the FDA and may be available."

Answered by AI

What are the side effects of Limbitrol?

"The following effects may occur: drowsiness, dizziness, dry mouth, blurred vision, constipation, bloating, trouble urinating, and weight gain. If you experience any of these effects, tell your doctor or pharmacist. To reduce the risk of dizziness or fainting, stand up slowly when you get up from a sitting or lying position."

Answered by AI

What is Limbitrol prescribed for?

"The drug LIMBITROL is indicated for the treatment of patients who have moderate to severe depression along with moderate to severe anxiety. The drug tends to work faster and with fewer treatment failures than when either amitriptyline or chlordiazepoxide are used alone."

Answered by AI

Clinical Trials for Limbitrol Ds

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Image of CVT in Centennial, United States.

Treatment for Anxiety Disorders

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Acceptance and Commitment Therapy for Inflammatory Bowel Disease

18+
All Sexes
Houston, TX

Many Veterans with gastrointestinal disorders, such as inflammatory bowel disease (IBD), also have mental health conditions. IBD and mental health conditions can worsen one another through the brain-gut axis, leading to dramatic deficits in psychosocial functioning and quality of life (QOL). Yet, few Veterans with comorbid IBD and mental health conditions receive psychotherapy and no evidence-based psychotherapies have been tested in Veterans with these comorbidities. Adapting brief acceptance and commitment therapy (ACT) to the specific to the needs of these patients and embedding treatment into routine gastroenterology care may increase Veterans' access to efficient and effective rehabilitative care. This study aims to adapt and test an integrated, 1-Day ACT intervention tailored to the specific needs of Veterans with IBD and mental health conditions to improve psychosocial functioning and QOL.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Mackenzie Lynmarie Shanahan, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Limbitrol Ds clinical trials?

We made a collection of clinical trials featuring Limbitrol Ds, we think they might fit your search criteria.
Go to Trials